Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Efficient in vitro screening for drug combinations: The TEVA model

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.07.19
Views: 114

Dr Angel Porgador - Ben-Gurion University of the Negev, Beersheeba, Israel

Dr Angel Porgador speaks to ecancer at the WIN 2019 Symposium in Paris about using in vitro screening to identify tailored and effective drug combinations for a patient.

Dr Porgador explains the process of using an in vitro method which uses a patient specimen to produce a patient-derived xenograft followed by an ex vivo assay.

He also discusses the issue of immunotherapy with this method in which patient T-cells can be extracted from the blood and later added to the ex vivo assay to ensure a tailored approach.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation